EUVIMEDEUVIMED entdecken
Open Access

Engineered FHA domains can bind to a variety of Phosphothreonine-containing peptides

Srinivas S Thota iD, Grace L Allen, Ashley K Grahn, Brian K Kay

Protein Engineering, Design and Selection · 29.01.2024 · 37

DOI: 10.1093/protein/gzae014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, online erschienen am 14.09.2024. Verfasst von Srinivas S Thota und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tango Biosciences, 2201 W. Campbell Park Drive, Chicago, IL 60612-4092 USA. Hauptthemen laut MEDLINE: Phosphothreonine, Protein Engineering. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Small Business Innovation Research, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies play a crucial role in monitoring post-translational modifications, like phosphorylation, which regulates protein activity and location; however, commercial polyclonal and monoclonal antibodies have limitations in renewability and engineering compared to recombinant affinity reagents. A scaffold based on the Forkhead-associated domain (FHA) has potential as a selective affinity reagent for this post-translational modification. Engineered FHA domains, termed phosphothreonine-binding domains (pTBDs), with limited cross-reactivity were isolated from an M13 bacteriophage display library by affinity selection with phosphopeptides corresponding to human mTOR, Chk2, 53BP1, and Akt1 proteins. To determine the specificity of the representative pTBDs, we focused on binders to the pT543 phosphopeptide (536-IDEDGENpTQIEDTEP-551) of the DNA repair protein 53BP1. ELISA and western blot experiments have demonstrated the pTBDs are specific to phosphothreonine, demonstrating the potential utility of pTBDs for monitoring the phosphorylation of specific threonine residues in clinically relevant human proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhosphothreonineProtein EngineeringHumansProtein BindingPeptide LibraryPhosphopeptidesPeptidesProtein DomainsPhosphorylationAmino Acid Sequence

Stichwörter der Autor:innen

53BP1Akt1Chk2FHA domainaffinity selectionlibrarymTORphosphoepitopephosphopeptidephosphoserinephosphothreoninesortase

Substanzen

PhosphothreoninePeptide LibraryPhosphopeptidesPeptides

Autor:innen und Institutionen

  • Tango Biosciences, 2201 W. Campbell Park Drive, Chicago, IL 60612-4092 USA.

ORCID-Profile: Srinivas S Thota

Förderung

  • NIGMS NIH HHS
  • Small Business Innovation Research
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Thota, S. S., Allen, G. L., Grahn, A. K., & Kay, B. K. (2024). Engineered FHA domains can bind to a variety of Phosphothreonine-containing peptides. Protein Engineering, Design and Selection, 37. https://doi.org/10.1093/protein/gzae014

Vancouver

Thota SS, Allen GL, Grahn AK, Kay BK. Engineered FHA domains can bind to a variety of Phosphothreonine-containing peptides. Protein Engineering, Design and Selection. 2024;37. doi:10.1093/protein/gzae014

BibTeX
@article{Thota2024,
  author = {Thota, Srinivas S and Allen, Grace L and Grahn, Ashley K and Kay, Brian K},
  title = {Engineered FHA domains can bind to a variety of Phosphothreonine-containing peptides},
  journal = {Protein Engineering, Design and Selection},
  year = {2024},
  volume = {37},
  doi = {10.1093/protein/gzae014}
}
Kostenlos starten →